Novartis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.04.17	GlobeNewswire/Novartis: ventes en progression -4- (Dow Jones)
24.04.17	Press Release: Novartis expands global -2- (Dow Jones)
24.04.17	Press Release: Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US a... (Dow Jones)
24.04.17	Press Release: Novartis real-world data at AAN -2- (Dow Jones)
24.04.17	Press Release: Novartis real-world data at AAN confirms benefit of Gilenya(R) on four key measures of disease activity in relapsing MS (Dow Jones)
21.04.17	Press Release: Novartis: Sandoz proposed -2- (Dow Jones)
21.04.17	Press Release: Novartis: Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe* (Dow Jones)
19.04.17	Press Release: NIH study in NEJM shows Novartis -2- (Dow Jones)
19.04.17	Press Release: NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia (Dow Jones)
18.04.17	Press Release: Novartis expands development -2- (Dow Jones)
18.04.17	Press Release: Novartis expands development programs for NASH through clinical collaboration with Allergan (Dow Jones)
18.04.17	Press Release: Novartis CAR-T cell therapy CTL019 -2- (Dow Jones)
18.04.17	Press Release: Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL (Dow Jones)
06.04.17	Press Release: Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications (Dow Jones)
03.04.17	Press Release: Novartis drug combination -3- (Dow Jones)
03.04.17	Press Release: Novartis drug combination -2- (Dow Jones)
03.04.17	Press Release: Novartis drug combination Tafinlar(R) + Mekinist(R) receives EU approval for BRAF V600-positive advanced non-small cell lung cancer (NSCLC) (Dow Jones)
29.03.17	Press Release: Novartis announces first CAR-T -2- (Dow Jones)
29.03.17	Press Release: Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review (Dow Jones)
23.03.17	Press Release: Alcon receives US FDA approval for -2- (Dow Jones)
23.03.17	Press Release: Alcon receives US FDA approval for new AcrySof(R) IQ ReSTOR(R) +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distanc... (Dow Jones)
22.03.17	Press Release: Novartis provides update on Phase -2- (Dow Jones)
22.03.17	Press Release: Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure (Dow Jones)
21.03.17	Press Release: Novartis' Cosentyx is first and -2- (Dow Jones)
21.03.17	Press Release: Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis (Dow Jones)
18.03.17	Press Release: New analysis shows Novartis -2- (Dow Jones)
18.03.17	Press Release: New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes (Dow Jones)
14.03.17	Press Release: Novartis Kisqali(R) (ribociclib, -2- (Dow Jones)
14.03.17	Press Release: Novartis Kisqali(R) (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination w... (Dow Jones)
13.03.17	Press Release: Sandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk) (Dow Jones)
06.03.17	Press Release: Novartis' Cosentyx shows almost -2- (Dow Jones)
06.03.17	Press Release: Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause (Dow Jones)
06.03.17	Press Release: Novartis: New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine (Dow Jones)
28.02.17	Press Release: Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting (Dow Jones)
28.02.17	GlobeNewswire/Novartis Aktionäre genehmigen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats (Dow Jones)
28.02.17	GlobeNewswire/Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration lors de l'Assemblée générale annuelle (Dow Jones)
24.02.17	Press Release: Novartis receives positive CHMP -3- (Dow Jones)
24.02.17	Press Release: Novartis receives positive CHMP -2- (Dow Jones)
24.02.17	Press Release: Novartis receives positive CHMP opinion for Tafinlar(R) + Mekinist(R) in BRAF-positive non-small cell lung cancer (NSCLC) patients (Dow Jones)
23.02.17	Press Release: Novartis drug Zykadia receives FDA -3- (Dow Jones)
23.02.17	Press Release: Novartis drug Zykadia receives FDA -2- (Dow Jones)
23.02.17	Press Release: Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC (Dow Jones)
31.01.17	Press Release: Novartis drug Votubia(R) receives -2- (Dow Jones)
31.01.17	Press Release: Novartis drug Votubia(R) receives EU approval to treat refractory partial-onset seizures in patients with TSC (Dow Jones)
26.01.17	Press Release: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report (Dow Jones)
26.01.17	Press Release: Novartis: Alcon launches new -2- (Dow Jones)
26.01.17	Press Release: Novartis: Alcon launches new trifocal toric intraocular lens for patients with astigmatism undergoing cataract surgery (Dow Jones)
25.01.17	Press Release: Novartis delivered solid 2016 -6- (Dow Jones)
25.01.17	Press Release: Novartis delivered solid 2016 -6- (Dow Jones)
25.01.17	Press Release: Novartis delivered solid 2016 -5- (Dow Jones)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	71.14	1.54 %	K V
UBS Group	28.08	1.48 %	K V
Swiss Re	130.05	1.05 %	K V
Part Grp Hldg	1’266.00	0.96 %	K V
ABB	49.48	0.94 %	K V
Geberit	525.20	0.27 %	K V
Alcon	78.04	0.05 %	K V
Givaudan	3’868.00	-0.31 %	K V
CieFinRichemont	121.20	-0.57 %	K V
Sonova Hldg	301.00	-0.99 %	K V

mehr

12.07.24		Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an
12.03.24		MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis
31.01.24		Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung
12.06.23		Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch
25.04.23		Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an
07.12.22		MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert
19.07.22		Novartis-Aktie höher: Novartis bei nahezu stabilen Umsätzen mit Gewinnrückgang - Umbau soll 1,5 Milliarden US-Dollar Kosten sparen
06.05.22		Novartis-Aktie im Minus: Produktion von Krebsmitteln in Italien und USA ausgesetzt

12.07.24

Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an

12.03.24

MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis

31.01.24

Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung

12.06.23

Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch

25.04.23

Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an

07.12.22

MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert